RhumbLine Advisers
TBIO

RhumbLine Advisers’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

RhumbLine Advisers’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-81,740
Closed -$2.25M – 3049
2021
Q2 		$2.25M Buy
81,740
+6,513
+9% +$128K ﹤0.01% 1895
2021
Q1 		$1.24M Sell
75,227
-5,315
-7% -$121K ﹤0.01% 2113
2020
Q4 		$1.48M Buy
80,542
+10,311
+15% +$185K ﹤0.01% 1982
2020
Q3 		$956K Buy
70,231
+1,478
+2% +$22.8K ﹤0.01% 2010
2020
Q2 		$1.23M Buy
68,753
+27,470
+67% +$414K ﹤0.01% 1956
2020
Q1 		$412K Buy
41,283
+2,761
+7% +$22.6K ﹤0.01% 2255
2019
Q4 		$314K Buy
38,522
+1,413
+4% +$13K ﹤0.01% 2570
2019
Q3 		$368K Sell
37,109
-240
-0.6% -$2.27K ﹤0.01% 2470
2019
Q2 		$472K Buy
37,349
+5,637
+18% +$59.4K ﹤0.01% 2386
2019
Q1 		$323K Buy
31,712
+21,397
+207% +$164K ﹤0.01% 2503
2018
Q4 		$77K Buy
+10,315
New +$75.6K ﹤0.01% 2908

RhumbLine Advisers's TBIO Position: Q3 2021 in Review

RhumbLine Advisers sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 81,740 shares — an estimated $2.25M sold.

RhumbLine Advisers first reported a position in TBIO in Q4 2018 and held it in 11 quarters. The position peaked at $2.25M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

  • RhumbLine Advisers reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 81,740 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $2.25M.
  • RhumbLine Advisers first reported a position in Translate Bio, Inc. Common Stock in Q4 2018 and held it in 11 quarters.
  • RhumbLine Advisers's Translate Bio, Inc. Common Stock position peaked at $2.25M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.